Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations
- PMID: 7226054
- DOI: 10.1002/1097-0142(19810315)47:6<1313::aid-cncr2820470613>3.0.co;2-o
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations
Abstract
This study compares thymidylate synthetase activity and certain aspects of fluorinated pyrimidine metabolism in tissue preparations derived from human colonic adenocarcinoma and from normal colonic mucosa. The purpose was to define differences that might be sufficient to explain the selective antitumor response of some colonic adenocarcinomas to 5-fluorouracil (FU) chemotherapy. Some carcinomas had much greater thymidylate synthetase activity than did other carcinomas and all normal mucosal preparations. Such carcinomas may be highly reliant on thymidylate synthetase and hence susceptible to its inhibition. Similarly, the smaller amount of FdUMP dephosphorylation found in all carcinomas compared with autologous normal mucosal preparations might result in prolonged thymidylate synthetase inhibition. In addition, greater thymidylate synthetase inhibition was produced by 1 X 10(-4) M FU in an occasional tumor than was found in normal mucosal preparations.
Similar articles
-
Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxy-uridine-5'-monophosphate.Eur J Cancer. 1991;27(3):263-7. doi: 10.1016/0277-5379(91)90512-c. Eur J Cancer. 1991. PMID: 1827310
-
Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft.Biochem Pharmacol. 1989 Jan 15;38(2):335-42. doi: 10.1016/0006-2952(89)90046-4. Biochem Pharmacol. 1989. PMID: 2914018
-
Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.Cancer Chemother Pharmacol. 1986;16(3):237-42. doi: 10.1007/BF00293984. Cancer Chemother Pharmacol. 1986. PMID: 3698165
-
Perspective on the design and biochemical pharmacology of inhibitors of thymidylate synthetase.J Med Chem. 1980 Feb;23(2):103-11. doi: 10.1021/jm00176a001. J Med Chem. 1980. PMID: 6987403 Review. No abstract available.
-
Fluorinated pyrimidines as tight-binding inhibitors of thymidylate synthetase.Pharmacol Ther. 1981;13(1):69-90. doi: 10.1016/0163-7258(81)90068-1. Pharmacol Ther. 1981. PMID: 6455671 Review. No abstract available.
Cited by
-
Difference in thymidylate synthetase activity in involved nodes compared with primary tumor in breast cancer patients.Breast Cancer Res Treat. 1995 Aug;35(2):157-62. doi: 10.1007/BF00668205. Breast Cancer Res Treat. 1995. PMID: 7647337